Vertex Pharmaceuticals Leaps After Phase 3 Studies Meet Primary Endpoints


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are trading higher by $20.00 (22.5 percent) at $110.17 in Wednesday's session.

The catalyst for the rally is the confirmation that two Phase 3 studies of Tezacaftor/Ivacaftor combo treatment net primary endpoints. The combo therapy significantly improved lung function in late stage trials.

Vertex's much higher opening print of $106.21 has turned out to be one penny from the low for the day at $106.20. The continuation rally has taken the issue to $111.88, which exceeds its January 11, 2016 high of $109.94, but is well shy of its January 8, 2016 high of $117.11.

The stock hasn't closed above $110.00 since January 8, 2016, when it ended the session at $110.71.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: TechnicalsIntraday UpdateMoversTrading Ideas